HARMONY BIOSCIENCES

Q1 2024 Financial Results

April 30, 2024

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies. These statements are based on current expectations or objectives that are inherently uncertain, especially in light of the Company's limited operating history. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 22, 2024 and its other filings with the SEC could cause actual results to differ materially and adversely from those indicated by the forward-looking statements made in this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the Company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.

Harmony Accelerates Growth Strategy
Three CNS Franchises - Each With Peak Sales Potential of $1B-$2B

Sleep/Wake

- **WAKIX potential $1B+ Net Revenue opportunity** in Narcolepsy alone with LOE out to 2030
- **On track towards pediatric exclusivity** to extend WAKIX exclusivity to September 2030
- **Near term catalysts** with potential new indications for pitolisant
  - **Pediatric Narcolepsy** – June 21, 2024 PDUFA
  - **IH** – sNDA planned for 2H 2024
- **Life cycle management for pitolisant with Next-Gen formulations** to extend the franchise revenue growth potential beyond 2040
  - **NG1 –** PDUFA date in 2026
  - **NG2 –** On track for PK data in 1H 2024
- **Strengthens leadership position with TPM-1116**, a highly potent and selective oral orexin-2 receptor agonist

Neurobehavioral

- **ZYN002 in Phase 3 RECONNECT study** for Fragile X syndrome (FXS); topline data expected Mid-2025
- **Phase 3 preparation ongoing** for 22q11.2(22q) deletion syndrome
- **A global opportunity** with **80,000 patients** each in FXS and 22q in the U.S. alone

Rare Epilepsy

- Establishes franchise through acquisition of Epygenix Therapeutics Inc.
- Lead product, clemizole hydrochloride(EPX-100), **in pivotal registrational trial for Dravet syndrome (DS)**; topline data expected in 2026
- **Phase 3 trial for Lennox-Gastaut** syndrome (LGS) to initiate 2H 2024
- EPX-100 **has Orphan Drug Designation and Rare Pediatric Disease Designation** from FDA for both DS and LGS
- EPX-200 in IND-enabling stage

WAKIX® Net Revenue Performance

CONFIDENT IN WAKIX BEING A POTENTIAL $1B+ OPPORTUNITY IN ADULT NARCOLEPSY ALONE



HIGHLIGHTS

- Durable sales into year five on the market with 30% growth year-over-year
- Underlying demand drove continued revenue growth
  - Strong patient interest
  - Continue to add new prescribers and grow WAKIX prescriber base

Solid Business Fundamentals Driving Growth



Q1 24 Highlights

~6,300 Average number of patients on WAKIX and growing

On our way to a $1B+ opportunity in adult narcolepsy

More unique prescribers of WAKIX® than sodium oxybate

Strong market access coverage (>80%) – *even with the availability of generic and new oxybate options*

1. Net Patient Additions based on previously disclosed quarterly average number of patients on WAKIX

Prescriber Dynamics Support Continued WAKIX® Growth in Adult Narcolepsy

~9,000
Narcolepsy Treating HCPs

Harmony Field Sales Team covers narcolepsy treating HCP universe

Access to ~100% of diagnosed adult patient opportunity

~4,000 HCPs enrolled in oxybate REMS

~5,000 HCPs not enrolled in oxybates REMS

WAKIX **growth**

Depth of prescribing in oxybate REMS enrolled HCPs

Breadth of prescribing in HCPs not enrolled in oxybate REMS

100% of HCPs surveyed with WAKIX experience stated they would write the **same/increase Rx in next 6 months**.[1]

~50% of HCPs surveyed who had not prescribed WAKIX to date indicated intent to **Rx in next 6 months**.[1]

Unique feature as **non-scheduled treatment** is the **highest performing driver and differentiator for WAKIX.**[1]

1. Harmony Market Research, January 2024

Building a Robust Late-Stage Pipeline

Extending the Pitolisant Franchise With Next-Gen Formulations (NG1)

Next-Gen Formulation 1

- **Description:** Enteric coated tablet formulation of pitolisant HCl
- **Clinical Development Objectives:**
  - Demonstrate bioequivalence (BE) to WAKIX; Abbreviated development program
  - Dosing optimization
- **Clinical Differentiation:**
  - Enteric coated tablet designed to potentially decrease GI side effects
  - Ability to start dosing at 17.8mg, at the beginning of the therapeutic range with potential to achieve clinical benefit faster
- **Market Opportunity:**
  - Unique product offering for patients to co-exist with WAKIX; accretive opportunity
  - Target patients with previous WAKIX experience
- **PDUFA date expected in 2026**
- **Provisional patent filed with the potential for patent protection out to 2044**

NG1 – Pilot Bioequivalence Study Data

Formulation	Cmax (ng/ml)	AUC_{0-t} (h*ng/ml)	AUC_{0-inf} (h*ng/ml)
Test formulation, NG1 (Enteric Coated Pitolisant Hcl)	15.29	242.27	256.62
Reference formulation, Wakix (Pitolisant Hcl)	14.42	224.12	237.22

- Cmax and AUC, the two important parameters to establish Bioequivalence (BE), are similar between the Test and the Reference formulations indicating the rate and extent of absorption are similar in this pilot study
- Safety and tolerability: No AEs reported either with the test or the reference formulations
- **Next Steps:**
  - Pivotal BE study – Q4 24
  - Dosing Optimization study – Q4 24
  - PDUFA Date – 2026

Extending the Pitolisant Franchise With Next-Gen Formulations (NG2)

ON TRACK FOR DATA IN FIRST HALF OF 2024

Next-Gen Formulation 2

- **Opportunity:** Extend franchise beyond 2040, with potential for new IP and opportunity to explore additional indications
- **Formulation:** Enhanced formulation designed to deliver an optimized PK profile and a higher dosage strength
- **Program:** Full development program
- **Status:** Pilot PK study initiated in Q4 23; data available in 1H 24

ARGUS Study in Dravet Syndrome



Trial Design:

- Randomized, double-blind, placebo-controlled, parallel-group study
- 1:1 clemizole hydrochloride: placebo
- ~100 patients; Age 2 years or older

Objectives / Endpoints:

- **Primary objective:** To evaluate the efficacy of EPX-100 compared with placebo as adjunctive therapy in children and adult participants with Dravet Syndrome
- **Primary endpoint:** Mean percent change between EPX-100 vs placebo in countable convulsive seizure frequency (CCSF)
- **Secondary Objective:** To evaluate the difference between EPX100 vs placebo in the number of countable convulsive seizure-free days relative to baseline
- **Secondary Endpoint:** The number of countable convulsive seizure-free days in the titration and maintenance phase relative to baseline

Financial Highlights

(In millions, USD)

Three Months Ended March 31, 2024

Net Product Revenue



Non-GAAP Adjusted Net Income(1)



Cash, Cash Equivalents & Investments



HIGHLIGHTS

- Durable sales into year five on the market with 30% growth year-over-year
- Improved profitability
- Continued cash generation resulting in a strong balance sheet

(1) Non-GAAP Adjusted Net Income= GAAP Net Income excluding non-cash interest expense, depreciation, amortization, stock-based compensation, other non-operating items and tax effect of these items

Financial Summary

(In millions, USD) Totals may not foot due to rounding	Three Months Ended March 31,		% Change
	2024	2023	
Net Product Revenue	**$154.6**	**$119.1**	**30%**
Cost of Product Sold	27.5	20.8	32%
Total Operating Expenses	**$75.1**	**$57.9**	**30%**
R&D Expense	22.2	13.3	67%
S&M Expense	27.2	22.6	21%
G&A Expense	25.7	22.1	16%
Net Income	**$38.3**	**$29.5**	**30%**
Cash, cash equivalents & investments	**$453.6**		

GAAP vs NON-GAAP Reconciliation

(In millions, USD) Totals may not foot due to rounding	Three Months Ended March 31,	
	2024	2023
GAAP net income	**$38.3**	**$29.5**
Non-cash interest expense(1)	0.2	0.4
Depreciation	0.2	0.1
Amortization(2)	6.0	6.0
Stock-based compensation expense	10.4	6.6
Licensing fees and milestone payments(3)	-	0.8
Income tax effect related to Non-GAAP adjustments(4)	(4.4)	(2.5)
Non-GAAP adjusted net income	**$50.7**	**$40.7**
GAAP net income per diluted share	**$0.67**	**$0.48**
Non-GAAP adjusted net income per diluted share	**$0.88**	**$0.67**
Weighted average number of shares of common stock used in non-GAAP diluted per share	57,597,627	61,221,511

(1) Includes amortization of deferred finance charges.
(2) Includes amortization of intangible asset related to WAKIX.
(3) Includes milestone payment related to HBS-102 preclinical milestone in March 2023.
(4) Calculated using the reported effective tax rate for the periods presented less impact of valuation allowance release and discrete items.

Reiterates 2024 Net Revenue Guidance

CONFIDENT IN WAKIX BEING A POTENTIAL $1B+ OPPORTUNITY IN ADULT NARCOLEPSY ALONE



Reiterates 2024 Guidance

$700-$720M

HARMONY BIOSCIENCES

Thank You!